Doctors have given their assessment of a new drug that is designed to fight HIV.
The lenacapavir trials conducted by the American company Gilead Sciences are a huge success.
The head of the AIDS center, Vadim Pokrovsky, expressed this opinion in an interview with RBC .
The trial in question involved a drug called lenacapavir that was conducted in South Africa and Uganda.
The study involved 5,300 women. Of those who received injections of the innovative drug twice a year, none contracted HIV.
At the same time, those who took the pills ended up contracting a deadly infection.
As Pokrovsky noted, the innovative nature of the drug lies precisely in the fact that it is administered by injection.
Previously, pre-exposure prophylaxis was only available in the form of tablets. And if you miss even one dose, and the drug must be taken strictly every day, then infection will occur.
This is why women with HIV were found in the group of subjects who took the pills.
Author: Irina Tint
